Needham & Company LLC Issues Pessimistic Forecast for LivaNova (NASDAQ:LIVN) Stock Price

LivaNova (NASDAQ:LIVN) had its price objective reduced by stock analysts at Needham & Company LLC from $75.00 to $64.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Needham & Company LLC’s price target points to a potential upside of 56.36% from the company’s previous close.

Several other analysts also recently issued reports on the company. Robert W. Baird lifted their price target on LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. Wolfe Research lowered LivaNova from an “outperform” rating to a “peer perform” rating in a research report on Wednesday. StockNews.com raised LivaNova from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 14th. Finally, Mizuho lowered their price objective on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating on the stock in a report on Thursday, October 31st. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $64.20.

LivaNova Stock Down 1.3 %

Shares of LIVN stock opened at $40.93 on Wednesday. The company has a market capitalization of $2.22 billion, a price-to-earnings ratio of 97.45 and a beta of 1.00. LivaNova has a 12-month low of $40.37 and a 12-month high of $64.47. The firm has a fifty day moving average of $47.52 and a 200-day moving average of $49.50. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46.

Insider Buying and Selling at LivaNova

In other news, Director Francesco Bianchi sold 1,250 shares of the stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $50.99, for a total value of $63,737.50. Following the completion of the sale, the director now owns 7,522 shares of the company’s stock, valued at approximately $383,546.78. This represents a 14.25 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.27% of the company’s stock.

Hedge Funds Weigh In On LivaNova

A number of institutional investors have recently added to or reduced their stakes in LIVN. State of Alaska Department of Revenue grew its position in shares of LivaNova by 7.3% in the 3rd quarter. State of Alaska Department of Revenue now owns 6,246 shares of the company’s stock valued at $328,000 after acquiring an additional 425 shares during the period. abrdn plc lifted its stake in LivaNova by 43.8% in the 3rd quarter. abrdn plc now owns 232,025 shares of the company’s stock valued at $12,191,000 after purchasing an additional 70,618 shares during the last quarter. Emerald Advisers LLC grew its holdings in LivaNova by 2.1% during the third quarter. Emerald Advisers LLC now owns 695,505 shares of the company’s stock worth $36,542,000 after purchasing an additional 14,302 shares during the period. Atria Investments Inc increased its position in LivaNova by 6.2% during the third quarter. Atria Investments Inc now owns 5,653 shares of the company’s stock worth $297,000 after buying an additional 331 shares during the last quarter. Finally, State of New Jersey Common Pension Fund D raised its stake in LivaNova by 38.3% in the third quarter. State of New Jersey Common Pension Fund D now owns 42,539 shares of the company’s stock valued at $2,235,000 after buying an additional 11,782 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.